Oral contraceptives to prevent pregnancy and diminish...

Details Oral contraceptives to prevent pregnancy and diminish... Oral contraceptives to prevent pregnancy and diminish...

2007-08-17

2009-11-10

Hui, San-ming (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S171000, C514S649000

Reexamination Certificate

active

07615545

ABSTRACT:
This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.

REFERENCES:
patent: 3568828 (1971-03-01), Lerner
patent: 4145416 (1979-03-01), Lachnit-Fixson et al.
patent: 4171358 (1979-10-01), Black
patent: 4215691 (1980-08-01), Wong
patent: 4291014 (1981-09-01), Keith et al.
patent: 4292315 (1981-09-01), Vorys
patent: 4390531 (1983-06-01), Edgren
patent: 4438139 (1984-03-01), Keith et al.
patent: 4530839 (1985-07-01), Pasquale
patent: 4534468 (1985-08-01), Nuckols et al.
patent: 4544554 (1985-10-01), Pasquale
patent: 4616006 (1986-10-01), Pasquale
patent: 4628051 (1986-12-01), Pasquale
patent: 4685911 (1987-08-01), Konno et al.
patent: 4736849 (1988-04-01), Leonard et al.
patent: 4752478 (1988-06-01), Bondi et al.
patent: 4762717 (1988-08-01), Crowley, Jr.
patent: 4962098 (1990-10-01), Boissonneault
patent: 4971998 (1990-11-01), Wurtman et al.
patent: 5010070 (1991-04-01), Boissonneault
patent: 5043331 (1991-08-01), Hirvonen et al.
patent: 5098714 (1992-03-01), Wright et al.
patent: 5108995 (1992-04-01), Casper
patent: 5208225 (1993-05-01), Boissonneault et al.
patent: 5256421 (1993-10-01), Casper
patent: 5262408 (1993-11-01), Bergink
patent: 5276022 (1994-01-01), Casper
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5340584 (1994-08-01), Spicer et al.
patent: 5382573 (1995-01-01), Casper
patent: 5510341 (1996-04-01), Ehrlich et al.
patent: 5552394 (1996-09-01), Hodgen
patent: 5567695 (1996-10-01), Labrie
patent: 5585370 (1996-12-01), Casper
patent: 5633242 (1997-05-01), Oettel et al.
patent: 5662927 (1997-09-01), Ehrlich et al.
patent: RE35724 (1998-02-01), Pasquale
patent: 5747480 (1998-05-01), Gast
patent: 5753639 (1998-05-01), Labrie
patent: 5756490 (1998-05-01), Lachnit et al.
patent: 5827843 (1998-10-01), Koninckx
patent: 5858405 (1999-01-01), Gast
patent: 5891867 (1999-04-01), Lanquetin et al.
patent: 5898032 (1999-04-01), Hodgen
patent: RE36247 (1999-07-01), Plunkett et al.
patent: 5980940 (1999-11-01), Spona et al.
patent: 6027749 (2000-02-01), Schmidt-Gollwitzer et al.
patent: 6028064 (2000-02-01), Rodriguez et al.
patent: 6139873 (2000-10-01), Hughes, Jr. et al.
patent: 6214815 (2001-04-01), Shangold et al.
patent: 6251956 (2001-06-01), Kafrissen et al.
patent: 6265393 (2001-07-01), Heinrichs
patent: 6306914 (2001-10-01), de Ziegler et al.
patent: 6312722 (2001-11-01), Schmidt-Gollwitzer et al.
patent: 6319911 (2001-11-01), Rodriguez
patent: RE37838 (2002-09-01), Spona et al.
patent: 6451779 (2002-09-01), Hesch
patent: 6479475 (2002-11-01), Gast
patent: 6500814 (2002-12-01), Hesch
patent: 6511970 (2003-01-01), Rodriguez
patent: 6765002 (2004-07-01), Rodriguez
patent: 6787531 (2004-09-01), Hilman et al.
patent: 7150355 (2006-12-01), Coe et al.
patent: RE39861 (2007-09-01), Hodgen
patent: 7320969 (2008-01-01), Bell et al.
patent: 7427609 (2008-09-01), Leonard
patent: 2001/0044431 (2001-11-01), Rodriguez
patent: 2002/0132801 (2002-09-01), Heil et al.
patent: 2003/0018018 (2003-01-01), Hodgen et al.
patent: 2003/0114429 (2003-06-01), Hilman et al.
patent: 2003/0119798 (2003-06-01), Heil et al.
patent: 2003/0144258 (2003-07-01), Heil et al.
patent: 2003/0216366 (2003-11-01), Leonard et al.
patent: 2003/0229057 (2003-12-01), Caubel et al.
patent: 2004/0009960 (2004-01-01), Heil et al.
patent: 2004/0142914 (2004-07-01), Friedman et al.
patent: 2004/0220152 (2004-11-01), Ben-Maimon et al.
patent: 2004/0222123 (2004-11-01), Niemann
patent: 2004/0251301 (2004-12-01), Niemann et al.
patent: 2005/0064031 (2005-03-01), Stockemann et al.
patent: 2005/0143359 (2005-06-01), Bell et al.
patent: 2006/0135496 (2006-06-01), DiLiberti et al.
patent: 2007/0111975 (2007-05-01), DiLiberti et al.
patent: 2007/0158233 (2007-07-01), Coe et al.
patent: 2008/0125402 (2008-05-01), DiLiberti et al.
patent: 2008/0132473 (2008-06-01), Bell et al.
patent: 1189101 (1998-07-01), None
patent: 0 253 607 (1988-01-01), None
patent: 0 911 029 (2002-04-01), None
patent: WO 93/17686 (1993-09-01), None
patent: WO 98/04246 (1998-02-01), None
patent: WO 98/04266 (1998-02-01), None
patent: WO 98/04267 (1998-02-01), None
patent: WO 00/38691 (2000-07-01), None
patent: WO 02/03975 (2002-01-01), None
patent: WO 2004/080442 (2004-09-01), None
patent: WO 2005/032558 (2005-04-01), None
Davies, G.C., et al., “Ovarian Activity And Bleeding Patterns During Extended Continuous Use Of A Combined Contraceptive Vaginal Ring,”Contraception 46:269-278, Elsevier (1992).
Hillard, P.J., “Oral contraception noncompliance: the extent of the problem,”Adv. Contracept. 8:13-20, Kluwer Academic (1992).
Koetsawang, S., et al., “A randomized, double-blind study of six combined oral contraceptives,”Contraception 25:231-241, Elsevier (1982).
Rosenberg, M.J., and Waugh, M.S., “Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons,”Am. J. Obstet. Gynecol. 179:577-582, Elsevier (1998).
Threlkeld, D.S., ed., “Oral Contraceptives,” inDrug Facts and Comparisons, Facts and Comparisons, St. Louis, MO, pp. 257-268 (1985).
Walker, A., and, Bancroft, J., “Relationship Between Premenstrual Symptoms and Oral Contraceptive Use: A Controlled Study,”Psychosom. Med. 52:86-96, Lippincott Williams & Wilkins (1990).
Ware, M., et al., ed., “Oral Contraception and Depression,”Br. Med. J. 4:380-381, British Medical Association (1969).
World Health Organization Scientific Group, “8. Risks With Particular Reference To Neoplasia Of Therapeutic Estrogens And Progestins Given to Peri- And Postmenopausal Women,” inResearch on the Menopause, World Health Organization, Geneva, Switzerland, pp. 52-69 (1981).
International Preliminary Examination Report for International Application No. PCT/US02/38602, completed on Jul. 9, 2004, European Patent Office, Munich, Germany.
International Search Report for International Application No. PCT/US04/013589, mailed on Mar. 9, 2006, U.S. Patent Office, Alexandria, Virginia.
Written Opinion for International Application No. PCT/US04/013589, completed on Nov. 11, 2005, Alexandria, Virginia.
Written Opinion for International Application No. PCT/US04/22829, completed on Sep. 18, 2006, U.S. Patent Office, Alexandria, Virginia.
Co-pending U.S. Appl. No. 12/162,445, inventors DiLiberti and Reape, filed Jan. 29, 2007 (Not Yet Published).
American Psychiatric Association, “Premenstrual Dysphoric Disorder,” inDSM-IV™:Diagnostic and Statistical Manual of Mental Disorders, 4thedition, American Psychiatric Association, Washington, DC, pp. 715-718 (1994).
Annex I of Declaration of Dr. Anne Szarewski (Document D27 in the Opposition to European Patent No. EP 0 911 029 B1), Szarewski, A.M.,Curriculum Vitae, 14 pages.
Annex II of Declaration of Dr. Anne Szarewski (Document D27 in the Opposition to European Patent No. EP 0 911 029 B1), “Commercially Available Monophasic Combined Oral Contraceptive Pills,” and “Ratio of equivalence given in patent EP 0 911 029 B1”.
Annex III of Declaration of Dr. Anne Szarewski (Document D27 in Opposition to European Patent No. EP 0 911 029 B1), Belsey, E.M., “The Association Between Vaginal Bleeding Patterns and Reasons for Discontinuation of Contraceptive Use,”Contraception 38:207-225, Elsevier (1988).
Annex IV of Declaration of Dr. Anne Szarewski (Document D27 in Opposition to European Patent No. EP 0 911 029 B1), Benagiano, G. and Fraser, I., The Depo-Provera Debate, Commentary on the Article “Depo-Provera, A Critical Analysis,” in:Contraception 24:493-528, Elsevier (1981).
Annex V of Declaration of Dr. Anne Szarewski (Document D27 in Opposition to European Patent No. EP 0 911 029 B1), “Is Cerazette the minipill of choice?,”Drug Ther. Bull. 41:1-3, Consumers' Association (Sep. 2003).
Annex VI of Declaration of Dr. Anne Szarewski (Document D27

Affiliated with

Also associated with

Rating

Oral contraceptives to prevent pregnancy and diminish... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral contraceptives to prevent pregnancy and diminish..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral contraceptives to prevent pregnancy and diminish... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4136179